Treating tobacco dependence: Review of the best and latest treatment options

Jon O. Ebbert, Amit Sood, J. Taylor Hays, Lowell C. Dale, Richard D. Hurt

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Globally, an estimated 85% of lung cancer in men and 47% of lung cancer in women is attributable to tobacco smoking. Tobacco dependence treatment remains the most cost-effective way to prevent morbidity and mortality from lung cancer. Several effective pharmacotherapies are available to treat tobacco dependence. However, the long-term effectiveness of these treatments has been limited because the majority of smokers who attempt to stop smoking eventually relapse. Approaching the treatment of tobacco use and dependence as a chronic disease and the development of innovative drug therapies offer new hope for the treatment of tobacco-dependent patients. The diagnosis of lung cancer provides a teachable moment to motivate patients to attempt tobacco abstinence on which clinicians should capitalize. We review the currently available pharmacologic approaches to the treatment of tobacco dependence.

Original languageEnglish (US)
Pages (from-to)249-256
Number of pages8
JournalJournal of Thoracic Oncology
Issue number3
StatePublished - Mar 2007


  • Bupropion
  • Drug therapy
  • Nicotine
  • Smoking cessation
  • Tobacco use cessation
  • Varenicline

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Treating tobacco dependence: Review of the best and latest treatment options'. Together they form a unique fingerprint.

Cite this